Literature DB >> 19300890

Regional origin and decrease of pain in patients with depressive symptoms under treatment with venlafaxine.

Stefan Begré1, Martin Traber, Martin Gerber, Roland von Känel.   

Abstract

OBJECTIVE: Patient's language, tradition, conventions, and customs may all determine integration into a society and are also part of the doctor-patient relationship that influences diagnostic and therapeutic outcome. Language barrier and sociocultural disparity of Eastern and Southern European patients may hamper recovery from pain and depression compared to Middle European patients in Switzerland.
METHODS: In a prospective naturalistic observational trial we investigated the influence of regional origin on treatment outcome in 420 pain sufferers with depressive symptoms from all over Switzerland who were treated with venlafaxine by 122 physicians in primary care. Physicians rated severity of depressive symptoms using the clinical global impression severity scale and pain intensity by means of visual analogue scales. We hypothesized that in Eastern and Southern European patients the magnitude of pain reduction under treatment with venlafaxine is less compared to Middle European patients.
RESULTS: Three months after study entry, Middle European patients were found to profit more from treatment with venlafaxine in terms of severity of depression and pain intensity than patients from Eastern Europe and Southern Europe.
CONCLUSION: Regional origin may contribute to the magnitude of pain reduction in patients with depressive symptoms under treatment with venlafaxine. Our results provide a rational for care provider educational programs aimed at improving capacities in treating patients from different regional origin with psychosomatic complaints such as depression and comorbid pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300890     DOI: 10.1007/s00127-009-0036-2

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  30 in total

1.  Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression.

Authors:  P Mbaya
Journal:  Hum Psychopharmacol       Date:  2002-10       Impact factor: 1.672

2.  What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?

Authors:  Borwin Bandelow; David S Baldwin; Ornah T Dolberg; Henning Friis Andersen; Dan J Stein
Journal:  J Clin Psychiatry       Date:  2006-09       Impact factor: 4.384

3.  The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study.

Authors:  A Yucel; S Ozyalcin; G Koknel Talu; E Kiziltan; B Yucel; O K Andersen; L Arendt-Nielsen; R Disci
Journal:  Eur J Pain       Date:  2004-11-13       Impact factor: 3.931

4.  Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting.

Authors:  L C Adelman; J U Adelman; R Von Seggern; L K Mannix
Journal:  Headache       Date:  2000 Jul-Aug       Impact factor: 5.887

5.  Outcomes of newly referred neurology outpatients with depression and pain.

Authors:  L S Williams; W J Jones; J Shen; R L Robinson; K Kroenke
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

6.  Venlafaxine treatment of fibromyalgia.

Authors:  Kemal Sayar; Gokhan Aksu; Ismail Ak; Mehmet Tosun
Journal:  Ann Pharmacother       Date:  2003-11       Impact factor: 3.154

7.  Ethnocultural influences on variation in chronic pain perception.

Authors:  Maryann S Bates; Thomas W Edwards; Karen O Anderson
Journal:  Pain       Date:  1993-01       Impact factor: 6.961

8.  Impact of organized violence on illness experience of Turkish/Kurdish and Bosnian migrant patients in primary care.

Authors:  Denise Gilgen; Corina Salis Gross; Daniel Maeusezahl; Conrad Frey; Marcel Tanner; Mitchell G Weiss; Christoph Hatz
Journal:  J Travel Med       Date:  2002 Sep-Oct       Impact factor: 8.490

Review 9.  The economic burden of depression with painful symptoms.

Authors:  Paul E Greenberg; Stephanie A Leong; Howard G Birnbaum; Rebecca L Robinson
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

10.  Comorbid depression, chronic pain, and disability in primary care.

Authors:  Bruce A Arnow; Enid M Hunkeler; Christine M Blasey; Janelle Lee; Michael J Constantino; Bruce Fireman; Helena C Kraemer; Robin Dea; Rebecca Robinson; Chris Hayward
Journal:  Psychosom Med       Date:  2006 Mar-Apr       Impact factor: 4.312

View more
  3 in total

1.  [Characteristics of patients suffering from chronic pain with depressive symptoms in three different treatment settings].

Authors:  Stefan Begré; Martin Traber; Martin Gerber; Roland von Känel
Journal:  Med Klin (Munich)       Date:  2010-06-26

2.  Vitamin D Deficiency and Depressive Symptomatology in Psychiatric Patients Hospitalized with a Current Depressive Episode: A Factor Analytic Study.

Authors:  Roland von Känel; Nasser Fardad; Nadine Steurer; Nicole Horak; Esther Hindermann; Franz Fischer; Katharina Gessler
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

3.  Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review.

Authors:  Lester Darryl Geneviève; Andrea Martani; Maria Christina Mallet; Tenzin Wangmo; Bernice Simone Elger
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.